{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T14:34:36Z","timestamp":1789828476861,"version":"4.0.1"},"reference-count":84,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Diab Rep"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1007\/s11892-019-1266-7","type":"journal-article","created":{"date-parts":[[2019,11,20]],"date-time":"2019-11-20T17:03:52Z","timestamp":1574269432000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Adverse Effects of Glycemia-Lowering Medications in Type 2 Diabetes"],"prefix":"10.1007","volume":"19","author":[{"given":"Laleh","family":"Razavi-Nematollahi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faramarz","family":"Ismail-Beigi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,20]]},"reference":[{"key":"1266_CR1","doi-asserted-by":"publisher","first-page":"773","DOI":"10.2337\/db09-9028","volume":"58","author":"RA DeFronzo","year":"2009","unstructured":"DeFronzo RA. Banting lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58:773\u201395.","journal-title":"Diabetes"},{"key":"1266_CR2","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1016\/j.numecd.2017.10.006","volume":"27","author":"A Tura","year":"2017","unstructured":"Tura A, Bagger JI, Ferrannini E, Holst JJ, Knop FK, Vilsb\u00f8ll T, et al. Impaired beta cell sensitivity to incretins in type 2 diabetes is insufficiently compensated by higher incretin response. Nutr Metab Cardiovasc Dis. 2017;27:1123\u20139.","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"1266_CR3","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.ijcard.2014.12.017","volume":"181","author":"G Savarese","year":"2015","unstructured":"Savarese G, Perrone-Firaldi P, D\u2019 Amore C, et al. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in diabetic patients: a meta-analysis. Int J Cardiol. 2015;181:239\u201344.","journal-title":"Int J Cardiol"},{"key":"1266_CR4","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1161\/CIRCRESAHA.114.301958","volume":"114","author":"JR Ussher","year":"2014","unstructured":"Ussher JR, Drucker DJ. Cardiovascular actions of incretin-based therapies. Circ Res. 2014;114:1788\u2013803.","journal-title":"Circ Res"},{"key":"1266_CR5","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.2147\/DMSO.S212715","volume":"12","author":"NE Gharaibeh","year":"2019","unstructured":"Gharaibeh NE, Rahhal MN, Rahimi L, Ismail-Beigi F. SGLT-2 inhibitors as promising therapeutics for non-alcoholic fatty liver disease: pathophysiology, clinical outcomes, and future directions. Diabetes Metab Syndr Obes. 2019;12:1001\u201312.","journal-title":"Diabetes Metab Syndr Obes"},{"key":"1266_CR6","first-page":"402","volume":"5","author":"JJ Meier","year":"2004","unstructured":"Meier JJ, Nauck MA. The potential role of glucagon-like peptide 1 in diabetes. Curr Opin Investig Drugs. 2004;5:402\u201310.","journal-title":"Curr Opin Investig Drugs"},{"key":"1266_CR7","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311\u201322.","journal-title":"N Engl J Med"},{"key":"1266_CR8","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, Eliaschewitz FG, J\u00f3dar E, Leiter LA, et al. Semaglutide and cardiovascular outcome in patients with type 2 diabetes. N Engl J Med. 2016;375:1834\u201344.","journal-title":"N Engl J Med"},{"key":"1266_CR9","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/S0140-6736(08)61206-4","volume":"372","author":"DJ Drucker","year":"2008","unstructured":"Drucker DJ, Buse JB, Taylor K, Kendall DM, Trautmann M, Zhuang D, et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomized, open label, non-inferiority study. Lancet. 2008;372:1240\u201350.","journal-title":"Lancet"},{"key":"1266_CR10","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/S2213-8587(13)70214-6","volume":"2","author":"RE Partley","year":"2014","unstructured":"Partley RE, Nauck MA, Barnett AH, et al. Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs(HARMONY7):a randomized, open label, multicenter, non-inferiority phase 3 study. Lancet Diabetes Endocrinol. 2014;2:289\u201397.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1266_CR11","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1111\/dom.13172","volume":"20","author":"T Vilsboll","year":"2018","unstructured":"Vilsboll T, Bain SC, Leiter LA, et al. Semaglutide, reduction in glycated hemoglobin and the risk of diabetic retinopathy. Diabetes Obes Metab. 2018;20:889\u201397.","journal-title":"Diabetes Obes Metab"},{"key":"1266_CR12","doi-asserted-by":"publisher","first-page":"e001986","DOI":"10.1136\/bmjopen-2012-001986","volume":"3","author":"LE Robinson","year":"2013","unstructured":"Robinson LE, Holt TA, Rees K, Randeva HS, et al. Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systemic review and meta-analysis. BMJ Open. 2013;3:e001986.","journal-title":"BMJ Open"},{"key":"1266_CR13","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S0140-6736(12)61267-7","volume":"381","author":"JB Buse","year":"2013","unstructured":"Buse JB, Nauck M, Forest T, et al. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomized, open label study. Lancet. 2013;381:117\u201324.","journal-title":"Lancet"},{"key":"1266_CR14","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1016\/S0140-6736(14)60976-4","volume":"384","author":"KM Dungan","year":"2014","unstructured":"Dungan KM, Povedano ST, Forest T, et al. Once weekly dulaglutide versus once daily liraglutide in metformin- treated patients with type2 diabetes (AWARD-6): a randomized, open label, phase3, non-inferiority trial. Lancet. 2014;384:1349\u201357.","journal-title":"Lancet"},{"key":"1266_CR15","doi-asserted-by":"publisher","first-page":"966","DOI":"10.2337\/dc16-2747","volume":"40","author":"WM Steinberg","year":"2017","unstructured":"Steinberg WM, Buse JB, Ghorbani MLM. Amylase, lipase, and acute pancreatitis in people with type 2 diabetes treated with liraglutide: results from the LEADER randomized Trial. Diabetes Care. 2017;40:966\u201372.","journal-title":"Diabetes Care"},{"key":"1266_CR16","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s12933-017-0512-z","volume":"16","author":"Z Zhang","year":"2017","unstructured":"Zhang Z, Chen X, Lu P, et al. Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes. Cardiovasc Diabetol. 2017;16:31.","journal-title":"Cardiovasc Diabetol"},{"key":"1266_CR17","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1210\/jc.2010-2822","volume":"96","author":"JB Buse","year":"2011","unstructured":"Buse JB, Garber A, Rosenstock J, Schmidt WE, Brett JH, Videb\u00e6k N, et al. Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the liraglutide effect and action in diabetes (LEAD) trial. J Clin Endocrinol Metab. 2011;96:1695\u2013702.","journal-title":"J Clin Endocrinol Metab"},{"key":"1266_CR18","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1111\/1440-1681.12455","volume":"42","author":"HZ-X ChenX-W","year":"2015","unstructured":"ChenX-W HZ-X, Zhou Z-W, et al. Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for treatment of type 2 diabetes mellitus. Clin Exp Pharmacol Physiol. 2015;42:999\u20131024.","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"1266_CR19","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1111\/j.1463-1326.2009.01187.x","volume":"12","author":"P Aschner","year":"2010","unstructured":"Aschner P, Katzeff HL, Guo H, Sunga S, Williams-Herman D, Kaufman KD, et al. Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes. Diabetes Obes Metab. 2010;12:252\u201361.","journal-title":"Diabetes Obes Metab"},{"key":"1266_CR20","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","volume":"369","author":"BM Scirica","year":"2013","unstructured":"Scirica BM, Bhatt DL, Bruanwald E, et al. Saxagliptin and CV outcomes in patients with type 2 diabetes. N Engl J Med. 2013;369:1317\u201326.","journal-title":"N Engl J Med"},{"key":"1266_CR21","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1016\/S0140-6736(14)62225-X","volume":"385","author":"F Zannad","year":"2015","unstructured":"Zannad F, Cannon CP, Cushman WC, Bakris GL, Menon V, Perez AT, et al. Heart failure and mortality in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicenter, randomized and double blinded trial. Lancet. 2015;385:2067\u201376.","journal-title":"Lancet"},{"key":"1266_CR22","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1056\/NEJMoa1501352","volume":"373","author":"JB Green","year":"2015","unstructured":"Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, et al. Effects of sitagliptin on CV outcomes in type 2 diabetes. N Engl J Med. 2015;373:232\u201342.","journal-title":"N Engl J Med"},{"key":"1266_CR23","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s40265-014-0337-y","volume":"75","author":"AJ Scheen","year":"2015","unstructured":"Scheen AJ. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs. 2015;75:33\u201359.","journal-title":"Drugs"},{"key":"1266_CR24","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1111\/dom.12244","volume":"16","author":"M Monami","year":"2014","unstructured":"Monami M, Nardini C, Mannucci E. Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2014;16:457\u201366.","journal-title":"Diabetes Obes Metab"},{"key":"1266_CR25","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1016\/j.clinthera.2015.02.016","volume":"37","author":"CV Desouza","year":"2015","unstructured":"Desouza CV, Gupta N, Patel A. Cardiometabolic effects of a new class of antidiabetic agents. Clin Ther. 2015;37:1178\u201394.","journal-title":"Clin Ther"},{"key":"1266_CR26","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1161\/CIRCULATIONAHA.117.028268","volume":"137","author":"C Wanner","year":"2018","unstructured":"Wanner C, Lachin JM, Inzucchi SE, Fitchett D, Mattheus M, George J, et al. EMPA-REG OUTCOME Investigators. Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease. Circulation. 2018;137:119\u201329.","journal-title":"Circulation"},{"key":"1266_CR27","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1161\/CIRCULATIONAHA.117.032038","volume":"137","author":"KW Mahaffey","year":"2018","unstructured":"Mahaffey KW, Neal B, Perkovic V, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin for primary and secondary prevention of cardiovascular events: results from the CANVAS Program (Canagliflozin Cardiovascular Assessment Study). Circulation. 2018;137:323\u201334.","journal-title":"Circulation"},{"key":"1266_CR28","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"\u2022 Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy (CREDENCE trial). N Engl J Med. 2019;380:2295\u2013306. This study may advance the use of this agent in certain patients with chronic kidney disease due to proven safety and benefits.","journal-title":"N Engl J Med"},{"key":"1266_CR29","unstructured":"United States Food and Drug Administration (FDA) warns about rare occurrences of a serious infection of the genital area with SGLT2 inhibitors for diabetes. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability. Accesed 5\/16\/2019"},{"key":"1266_CR30","doi-asserted-by":"publisher","first-page":"e4","DOI":"10.2337\/dc17-1551","volume":"41","author":"SE Inzucchi","year":"2018","unstructured":"\u2022 Inzucchi SE, Iliev H, Pfarr E, Zinman B. Empagliflozin and assessment of lower-limb amputations in the EMPA-REG OUTCOME trial. Diabetes Care. 2018;41:e4\u20135. This study evaluates potential serious adverse effects of this class of glucose-lowering medications.","journal-title":"Diabetes Care"},{"key":"1266_CR31","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1111\/dom.13124","volume":"20","author":"S Jabbour","year":"2017","unstructured":"Jabbour S, Seufert J, Scheen A, Bailey CJ, Karup C, Langkilde AM. Dapagliflozin in patients with type 2 diabetes mellitus: a pooled analysis of safety data from phase IIb\/III clinical trials. Diabetes Obes Metab. 2017;20:620\u20138.","journal-title":"Diabetes Obes Metab"},{"issue":"11","key":"1266_CR32","doi-asserted-by":"publisher","first-page":"764","DOI":"10.7326\/M19-0085","volume":"170","author":"Susan J. Bersoff-Matcha","year":"2019","unstructured":"Bersoff-Matcha SJ, Chamberlain C, Cao C, et al. Fournier gangrene associated with sodium-glucose Cotransporter-2 inhibitors: a review of spontaneous postmarketing cases. Ann Intern Med. 2019. https:\/\/doi.org\/10.7326\/M19-0085.","journal-title":"Annals of Internal Medicine"},{"key":"1266_CR33","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1002\/phar.1881","volume":"37","author":"KR Burke","year":"2017","unstructured":"Burke KR, Schumacher CA, Harpe SE. SGLT2 inhibitors: a systematic review of diabetic ketoacidosis and related risk factors in the primary literature. Pharmacotherapy. 2017;37:187\u201394.","journal-title":"Pharmacotherapy"},{"key":"1266_CR34","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1111\/jdi.12401","volume":"7","author":"W Ogawa","year":"2016","unstructured":"Ogawa W, Sakaguchi K. Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: possible mechanism and contributing factors. J Diabetes Investig. 2016;7:135\u20138.","journal-title":"J Diabetes Investig"},{"key":"1266_CR35","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.2337\/dc15-1380","volume":"38","author":"J Rosenstock","year":"2015","unstructured":"Rosenstock J, Ferrannini E. Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors. Diabetes Care. 2015;38:1638\u201342.","journal-title":"Diabetes Care"},{"key":"1266_CR36","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1210\/jc.2015-3167","volume":"101","author":"NB Watts","year":"2016","unstructured":"Watts NB, Bilezikian JP, Usiskin K. Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2016;101:157\u201366.","journal-title":"J Clin Endocrinol Metab"},{"key":"1266_CR37","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.2146\/ajhp160319","volume":"74","author":"D Wolverton","year":"2017","unstructured":"Wolverton D, Blair MM. Fracture risk associated with common medications used in treating type 2 diabetes mellitus. Am J Health Syst Pharm. 2017;74:1143\u201351.","journal-title":"Am J Health Syst Pharm"},{"key":"1266_CR38","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644\u201357.","journal-title":"N Engl J Med"},{"key":"1266_CR39","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1161\/CIRCULATIONAHA.118.035901","volume":"138","author":"BL Neuen","year":"2018","unstructured":"Neuen BL, Ohkuma T, Neal B, Matthews DR, de Zeeuw D, Mahaffey KW, et al. Cardiovascular and renal outcomes with canagliflozin according to baseline kidney function. Circulation. 2018;138:1537\u201350.","journal-title":"Circulation"},{"key":"1266_CR40","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.1111\/dom.13413","volume":"20","author":"P Fioretto","year":"2018","unstructured":"\u2022 Fioretto P, Del Prato S, Buse JB, et al. Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study. Diabetes Obes Metab. 2018;20:2532\u201340. This study may advance the use of this agent in certain patients with chronic kidney disease due to proven safety and benefits.","journal-title":"Diabetes Obes Metab"},{"key":"1266_CR41","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380:347\u201357.","journal-title":"N Engl J Med"},{"key":"1266_CR42","doi-asserted-by":"publisher","first-page":"991","DOI":"10.2147\/TCRM.S86641","volume":"11","author":"M Chowdhary","year":"2015","unstructured":"Chowdhary M, Kabbani AA, Chhabra A. Canagliflozin-induced pancreatitis: a rare side effect of a new drug. Ther Clin Risk Manag. 2015;11:991\u20134.","journal-title":"Ther Clin Risk Manag"},{"key":"1266_CR43","doi-asserted-by":"publisher","first-page":"101","DOI":"10.4103\/0976-0105.160753","volume":"6","author":"N Srivali","year":"2015","unstructured":"Srivali N, Thongprayoon C, Cheungpasitporn W, Ungprasert P. Acute pancreatitis in the use of canagliflozin: a rare side-effect of the novel therapy for type 2 diabetes mellitus. J Basic Clin Pharm. 2015;6:101\u201312.","journal-title":"J Basic Clin Pharm"},{"issue":"5","key":"1266_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1463-1326.2009.01136.x","volume":"11","author":"AJ Garber","year":"2009","unstructured":"Garber AJ. Restaging insulin therapy for patients with type 2 diabetes. Diabetes Obes Metab. 2009;11(5):1\u20135.","journal-title":"Diabetes Obes Metab"},{"key":"1266_CR45","doi-asserted-by":"publisher","first-page":"f4533","DOI":"10.1136\/bmj.f4533","volume":"347","author":"A Goto","year":"2013","unstructured":"Goto A, Arah OA, Goto M, Terauchi Y, Noda M. Severe hypoglycaemia and cardiovascular disease: systematic review and meta-analysis with bias analysis. BMJ. 2013;347:f4533.","journal-title":"BMJ"},{"key":"1266_CR46","doi-asserted-by":"publisher","unstructured":"Swinnen SG, Simon AC, Holleman F, Hoekstra JB, Devries JH.Insulin detemir vs insulin glargene for type 2 diabetes mellitus.Cochrane Database Syst Rev. 2011 Jul 6;(7):CD006383. https:\/\/doi.org\/10.1002\/14651858.CD006383.pub2. Review.","DOI":"10.1002\/14651858.CD006383.pub2"},{"key":"1266_CR47","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1056\/NEJMoa1203858","volume":"367","author":"HC Gerstein","year":"2012","unstructured":"ORIGIN Trial Investigators, Gerstein HC, Bosch J, et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012;367:319\u201328.","journal-title":"N Engl J Med"},{"key":"1266_CR48","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1056\/NEJMoa1615692","volume":"377","author":"SP Marso","year":"2017","unstructured":"\u2022 Marso SP, McGuire DK, Zinman B, et al. Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes (DEVOTE). N Engl J Med. 2017;377:723\u201332. This study confirmed the CV safety of the novel insulin, degludec.","journal-title":"N Engl J Med"},{"key":"1266_CR49","doi-asserted-by":"publisher","first-page":"2.eCollection 2","DOI":"10.1186\/s13098-018-0397-3","volume":"11","author":"KFS Melo","year":"2019","unstructured":"Melo KFS, Bahia LR, Pasinato B, et al. Short-acting insulin analogues versus regular human insulin on postprandial glucose and hypoglycemia in type 1 diabetes mellitus: a systematic review and meta-analysis. Diabetol Metab Syndr. 2019;11:2.eCollection 2019.","journal-title":"Diabetol Metab Syndr"},{"issue":"2","key":"1266_CR50","doi-asserted-by":"publisher","first-page":"e0211820","DOI":"10.1371\/journal.pone.0211820","volume":"14","author":"Y Xu","year":"2019","unstructured":"Xu Y, Pilla SJ, Alexander GC, Murimi IB. Use of non-insulin diabetes medicines after insulin initiation: A retrospective cohort study. PLoS ONE. 2019;14(2):e0211820.","journal-title":"PLoS ONE"},{"key":"1266_CR51","doi-asserted-by":"publisher","first-page":"394","DOI":"10.7326\/M18-1149","volume":"169","author":"G Roglic","year":"2018","unstructured":"Roglic G, Norris SL. Medicines for treatment intensification in type 2 diabetes and type of insulin in type 1 and type 2 diabetes in low-resource settings: synopsis of the World Health Organization guidelines on second- and third-line medicines and type of insulin for the control of blood glucose levels in non pregnant adults with diabetes mellitus. Ann Intern Med. 2018;169:394\u20137.","journal-title":"Ann Intern Med"},{"key":"1266_CR52","first-page":"51","volume":"10","author":"FM Ashcroft","year":"1999","unstructured":"Ashcroft FM. Gribble FM.ATP sensitive K channels and insulin secretion: their role in health and disease. Diabetologia. 1999;10:51\u20138.","journal-title":"Diabetologia"},{"key":"1266_CR53","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1042\/bst0300333","volume":"30","author":"FM Gribble","year":"2002","unstructured":"Gribble FM, Reimann F. Pharmacological modulation of KATP channels. Biochem Soc Trans. 2002;30:333\u20139.","journal-title":"Biochem Soc Trans"},{"key":"1266_CR54","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1007\/s00125-003-1153-1","volume":"46","author":"P Rorsman","year":"2003","unstructured":"Rorsman P, Renstrom E. Insulin granule dynamics in pancreatic beta cells. Diabetologia. 2003;46:1029\u201345.","journal-title":"Diabetologia"},{"key":"1266_CR55","doi-asserted-by":"publisher","first-page":"223","DOI":"10.2165\/00002018-199411040-00002","volume":"11","author":"K Aj","year":"1994","unstructured":"Aj K, Fermer RE, Bailey CJ. Comparative tolerability profile of oral antidiabetic agents. Drug Saf. 1994;11:223\u201341.","journal-title":"Drug Saf"},{"key":"1266_CR56","doi-asserted-by":"publisher","first-page":"2642","DOI":"10.2337\/db09-0618","volume":"58","author":"PD Reaven","year":"2009","unstructured":"Reaven PD, Moritz TE, Schwenke DC, Anderson RJ, Criqui M, Detrano R, et al. Intensive glucose-lowering therapy reduces cardiovascular disease events in veterans affairs diabetes trial participants with lower calcified coronary atherosclerosis. Diabetes. 2009;58:2642\u20138.","journal-title":"Diabetes"},{"key":"1266_CR57","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.2337\/dc16-0024","volume":"39","author":"DE Bonds","year":"2016","unstructured":"\u2022\u2022 Bonds DE, Miller ME, Bergenstal RM, et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. Diabetes Care. 2016;39:1089\u2013100. This study is one of the pioneers in establishing adverse effects of glucose-lowering medications.","journal-title":"Diabetes Care"},{"key":"1266_CR58","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","volume":"352","author":"UK Prospective Diabetes Study Group","year":"1998","unstructured":"\u2022\u2022 UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837\u201353. This study is also one of the initial studies that introduced the adverse effects of glucose-lowering medications.","journal-title":"Lancet"},{"key":"1266_CR59","doi-asserted-by":"publisher","first-page":"352","DOI":"10.2165\/00002512-200118050-00003","volume":"18","author":"SH Wilson","year":"2001","unstructured":"Wilson SH, Kennedy FP, Garratt KN. Optimization of the management of patient with coronary heart disease and type 2 diabetes mellitus. Drugs Aging. 2001;18:352\u201333.","journal-title":"Drugs Aging"},{"key":"1266_CR60","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1111\/j.1365-2362.2004.01381.x","volume":"34","author":"G Schernthaner","year":"2004","unstructured":"Schernthaner G, Grimaldi A, Di Mario U, et al. GUIDE study: double blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients. Eur J Clin Investig. 2004;34:535\u201342.","journal-title":"Eur J Clin Investig"},{"key":"1266_CR61","first-page":"128","volume":"10","author":"CJ Bailey","year":"2003","unstructured":"Bailey CJ, Day C. Antidiabetic drugs. Br J Cardiol. 2003;10:128\u201336.","journal-title":"Br J Cardiol"},{"key":"1266_CR62","first-page":"139","volume":"7","author":"RA DeFronzo","year":"1999","unstructured":"DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med. 1999;7:139\u201353.","journal-title":"Ann Intern Med"},{"key":"1266_CR63","first-page":"1","volume":"13","author":"D Varvaki Rados","year":"2016","unstructured":"Varvaki Rados D, Catani Pinto L, Reck Remonti L, et al. The association between sulfonylurea use and all-cause and cardiovascular mortality: a meta-analysis with trial sequential analysis of randomized clinical trials. PLoS Med. 2016;13:1\u201322.","journal-title":"PLoS Med"},{"key":"1266_CR64","doi-asserted-by":"publisher","first-page":"411","DOI":"10.2165\/00002512-200017050-00007","volume":"17","author":"R Landgraf","year":"2000","unstructured":"Landgraf R. Meglitinide analogues in the treatment of type 2 diabetes mellitus. Drugs Aging. 2000;17:411\u201325.","journal-title":"Drugs Aging"},{"key":"1266_CR65","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1016\/S0140-6736(01)06715-0","volume":"358","author":"A Dornhorst","year":"2001","unstructured":"Dornhorst A. Insulinotropic meglitinide analogues. Lancet. 2001;358:1709\u201315.","journal-title":"Lancet"},{"key":"1266_CR66","first-page":"17","volume":"13","author":"M Davies","year":"2002","unstructured":"Davies M. Nateglinide: better post-prandial glucose control. Prescriber. 2002;13:17\u201327.","journal-title":"Prescriber"},{"key":"1266_CR67","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1056\/NEJM199602293340906","volume":"334","author":"CJ Bailey","year":"1996","unstructured":"Bailey CJ, Turner RC. Metformin. N Engl J Med. 1996;334:574\u20139.","journal-title":"N Engl J Med"},{"key":"1266_CR68","first-page":"89","volume":"6","author":"K Cusi","year":"1998","unstructured":"Cusi K, DeFronzo RA. Metformin: a review of its metabolic effects. Diabetes Rev. 1998;6:89\u2013131.","journal-title":"Diabetes Rev"},{"key":"1266_CR69","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1172\/JCI13505","volume":"108","author":"G Zhou","year":"2001","unstructured":"Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, et al. Role of AMP-activated protein kinase in the mechanism of action of metformin. J Clin Invest. 2001;108:1167\u201374.","journal-title":"J Clin Invest"},{"key":"1266_CR70","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1016\/S0140-6736(98)07037-8","volume":"352","author":"UKPDS group","year":"1998","unstructured":"UKPDS group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:854\u201365.","journal-title":"Lancet"},{"key":"1266_CR71","first-page":"61","volume-title":"Drug treatment of type 2 diabetes","author":"HCS Howlett","year":"2000","unstructured":"Howlett HCS, Bailey CJ. A risk-benefit assessment of metformin in type 2 diabetes mellitus. In: Aj K, editor. Drug treatment of type 2 diabetes. Auckland: Adis books; 2000. p. 61\u20137."},{"key":"1266_CR72","doi-asserted-by":"publisher","first-page":"925","DOI":"10.2337\/diacare.20.6.925","volume":"20","author":"T Sulkin","year":"1997","unstructured":"Sulkin T, Bosman D, Krentz AJ. Contraindications to metformin therapy in patients with NIDDM. Diabetes Care. 1997;20:925\u20138.","journal-title":"Diabetes Care"},{"key":"1266_CR73","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1046\/j.1464-5491.1999.00023.x","volume":"16","author":"C Day","year":"1999","unstructured":"Day C. Thiazolindiones: a new class of antidiabetic drugs. Diabet Med. 1999;16:1\u201314.","journal-title":"Diabet Med"},{"key":"1266_CR74","doi-asserted-by":"publisher","first-page":"37731","DOI":"10.1074\/jbc.R100034200","volume":"276","author":"ED Rosen","year":"2001","unstructured":"Rosen ED, Speigelman BM. PPAR-Gamma: a nuclear regulator of metabolism, differentiation and cell growth. J Biol Chem. 2001;276:37731\u20134.","journal-title":"J Biol Chem"},{"key":"1266_CR75","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1007\/s00125-003-1228-z","volume":"46","author":"M Fasshauer","year":"2003","unstructured":"Fasshauer M, Paschke R. Regulation of adipocytokines and insulin resistance. Diabetologia. 2003;46:1594\u2013603.","journal-title":"Diabetologia"},{"key":"1266_CR76","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1056\/NEJMoa072761","volume":"356","author":"SE Nissen","year":"2007","unstructured":"Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356:2457\u201371.","journal-title":"N Engl J Med"},{"key":"1266_CR77","unstructured":"European Medicine Agency, 2010. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/avandia. Accesed 9\/23\/2010"},{"key":"1266_CR78","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1016\/S0140-6736(09)60953-3","volume":"373","author":"PD Home","year":"2009","unstructured":"Home PD, Pocock SJ, Beck-Nielsen H, Curtis PS, Gomis R, Hanefeld M, et al. Rosiglitazone evaluated for cardiovascular outcome in oral agent combination for type 2 diabetes (RECORD): a multicenter, randomized, open label trial. Lancet. 2009;373:2125\u201335.","journal-title":"Lancet"},{"key":"1266_CR79","unstructured":"Avandia [package insert]. Research Triangle Park, NC:Glaxosmithkline;2011."},{"key":"1266_CR80","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1016\/j.jacc.2006.12.048","volume":"49","author":"E Erdmann","year":"2007","unstructured":"Erdmann E, et al. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: result from PROactive study. J Am Cardiol. 2007;49:1772\u201380.","journal-title":"J Am Cardiol"},{"issue":"10","key":"1266_CR81","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.2337\/dc16-0798","volume":"39","author":"SE Inzucchi","year":"2016","unstructured":"Inzucchi SE, Viscoli CM, Young LH. Pioglitazone prevents diabetes in patients with insulin resistance and cerebrovascular disease. Diabetes Care. 2016;39(10):1684\u201392.","journal-title":"Diabetes Care"},{"key":"1266_CR82","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1503\/cmaj.080486","volume":"180","author":"YK Loke","year":"2009","unstructured":"Loke YK, Singh S, Furberg CD. Long term use of thiazolindiones and fractures in type 2 diabetes: a meta-analysis. CMAJ. 2009;180:32\u20139.","journal-title":"CMAJ"},{"key":"1266_CR83","first-page":"132","volume":"6","author":"HE Lebovitz","year":"1998","unstructured":"Lebovitz HE. Alpha \u2013glucosidase inhibitors as agents in the treatment of diabetes. Diabetes Revs. 1998;6:132\u201345.","journal-title":"Diabetes Revs"},{"key":"1266_CR84","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1016\/S0140-6736(02)08905-5","volume":"359","author":"JL Chiasson","year":"2002","unstructured":"Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M, et al. Acarbose for the prevention of diabetes mellitus: the STOP-NIDDM randomized trial. STOP_NIDDM Trial research group. Lancet. 2002;359:2072\u20137.","journal-title":"Lancet"}],"container-title":["Current Diabetes Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11892-019-1266-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11892-019-1266-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11892-019-1266-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,17]],"date-time":"2022-04-17T09:17:38Z","timestamp":1650187058000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11892-019-1266-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":84,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["1266"],"URL":"https:\/\/doi.org\/10.1007\/s11892-019-1266-7","relation":{},"ISSN":["1534-4827","1539-0829"],"issn-type":[{"value":"1534-4827","type":"print"},{"value":"1539-0829","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"20 November 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Laleh Razavi-Nematollahi declares that she has no conflict of interest. Faramarz Ismail-Beigi is a consultant to COVANCE and Sanofi and has received research grants from Novo Nordisk.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"132"}}